Glyscend Therapeutics, a clinical-stage biotechnology company pioneering a new generation of orally administered polymer therapies, today announced the appointment of Michael Wyzga to its Board of Directors. Mr. Wyzga brings over two decades of deep experience leading and advising life sciences companies to the Glyscend Board.

“We are thrilled to welcome Mike, a distinguished biotech industry expert, to the Glyscend team,” said Ashish Nimgaonkar, M.D., President and CEO of Glyscend. “As we continue to progress our lead asset, GLY-200, through clinical development, his broad experience in leadership roles across the areas of finance, strategic planning and corporate development will be invaluable. I, along with the rest of the Board, look forward to his partnership.”

Mr. Wyzga added, “I’m pleased to join the Glyscend Board of Directors during this exciting time for the company. With encouraging findings observed with GLY-200 in Glyscend’s Phase 1 trial, I believe this drug, with its unique, gut-targeted approach, could provide a promising option to help patients achieve glycemic and bodyweight control in a highly convenient and safe manner. I look forward to working with Glyscend’s expert management team as the company continues to develop an innovative treatment option for Type 2 diabetes and obesity.”

Mr. Wyzga is the President of MSW Consulting, Inc., a private company focused on strategic biotechnology consulting, a position he has held since November 2013. Prior to that, he served as President, CEO and a member of the Board of Directors of Radius Health, Inc. From 1993 to 2011, Mr. Wyzga served in various senior management positions at Genzyme Corporation, including as Executive Vice President, Finance and as Chief Financial Officer. During his time with Genzyme, Mr. Wyzga played key roles in the successful development and commercialization of several important therapies, including Cerezyme for Gaucher disease, Fabrazyme for Fabry disease, Renagel for use in the treatment of hyperphosphatemia and Campath for chronic lymphocytic leukemia. Mr. Wyzga has served on many public company Boards, including at Invivyd, Inc., Mereo BioPharma Group plc, OncoMed Pharmaceuticals, Inc., X4 Pharmaceuticals, GenSight Biologics, LogicBio Therapeutics, Akebia Therapeutics, Inc., Idenix Pharmaceuticals, Inc., Prosensa Holding B.V. Mr. Wyzga received an MBA from Providence College and a B.S. from Suffolk University.

About Glyscend, Inc.

Glyscend Therapeutics is a clinical-stage biopharmaceutical company developing novel, orally administered, polymer therapies that work on targets inside the gastrointestinal tract to treat a variety of metabolic and chronic disorders. Polymer-based therapies are a unique class of therapeutics with more than three decades of clinical experience in a wide range of applications. Glyscend’s polymer technology platform evolved out of research at Johns Hopkins University where scientists were evaluating the mechanisms that result in significantly improved glucose and metabolic regulation that precedes weight loss in certain types of metabolic surgery. The company’s lead product candidate, GLY-200, is in clinical development initially for the treatment of Type 2 diabetes and/or obesity. In addition, Glyscend is exploring new program opportunities that address topical GI as well as systemic, inflammatory, and autoimmune conditions. The company is also investigating use of its technology platform to unlock novel GI tract targets using polymer-drug conjugates and to enhance the oral bioavailability of peptide therapies. For more information, please visit www.glyscend.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230330005094/en/

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.